Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222

PURPOSE: A SWOG pilot study (S0004) showed that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median survival of 22 months in limited-stage small-cell lung cancer (LSCLC). We report results of the phase II study designed to confirm this result. PATIENTS AND M...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Le, Quynh-Thu X., Moon, James, Redman, Mary, Williamson, Stephen K., Lara, Primo N., Goldberg, Zelanna, Gaspar, Laurie E., Crowley, John J., Moore, Dennis F., Gandara, David R.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2009
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2702233/
https://ncbi.nlm.nih.gov/pubmed/19364954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.3868
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars